MET and non-small cell lung carcinoma: Currently, savolitinib is primarily employed as a monotherapy for advanced NSCLC with METex14 skipping mutation, as well as in combination with EGFR-TKIs to overcome acquired resistance driven by MET to EGFR-TKIs (Sequist et al., 2020; Markham, 2021; Oxnard et al., 2020; Yu et al., 2024; Lee et al., 2023).